Cencora (NYSE:COR) Price Target Raised to $395.00

Posted by Brian Himes on Aug 14th, 2026

Cencora (NYSE:COR – Free Report) had its price target increased by Wells Fargo & Company from $331.00 to $395.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also recently weighed in on COR. Bank of America increased their price objective on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Morgan Stanley raised their price target on Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Barclays cut their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $374.25.

View Our Latest Stock Analysis on COR

Cencora Price Performance

Shares of Cencora stock opened at $310.13 on Tuesday. The company’s fifty day simple moving average is $298.20 and its two-hundred day simple moving average is $313.24. Cencora has a 12-month low of $244.82 and a 12-month high of $377.54. The firm has a market cap of $60.34 billion, a PE ratio of 23.04, a price-to-earnings-growth ratio of 1.81 and a beta of 0.57. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.00 earnings per share. As a group, equities analysts expect that Cencora will post 17.84 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th. Cencora’s dividend payout ratio is presently 17.83%.

Cencora declared that its board has initiated a share repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Cencora in the second quarter worth about $5,154,136,000. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares during the last quarter. Norges Bank bought a new stake in shares of Cencora in the 4th quarter worth approximately $822,506,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Cencora in the 2nd quarter worth approximately $483,772,000. Finally, Marshall Wace LLP grew its stake in shares of Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

Positive Sentiment: Wells Fargo issued a Buy rating on Cencora, providing a fresh bullish signal and potentially supporting the stock’s valuation. Wells Fargo Gives a Buy Rating to Cencora
Positive Sentiment: Brokerage coverage remains broadly constructive, with Cencora receiving an average “Moderate Buy” rating. Several recent price targets are above the current trading level, and Zacks highlighted the stock as a potential long-term value opportunity. Cencora Receives Moderate Buy Rating Why Cencora Is a Top Value Stock
Positive Sentiment: Long-term momentum arguments remain intact, supported by Cencora’s healthcare-distribution scale, recurring demand and recent earnings that exceeded consensus expectations for both revenue and adjusted EPS. Why Cencora Is a Top Momentum Stock
Neutral Sentiment: Analysts focused on customer concentration, pricing changes, GLP-1 demand and the outlook during Cencora’s earnings call. The questions underscore areas investors are monitoring but did not establish a new major catalyst. Five Analyst Questions From Cencora’s Earnings Call
Neutral Sentiment: Institutional positioning was mixed: 561 investors added shares while 802 reduced holdings. Large purchases by JPMorgan, Morgan Stanley and others were offset by reductions from BlackRock and Royal Bank of Canada, offering no clear consensus signal.
Negative Sentiment: Revenue-headwind concerns remain the primary pressure on COR. Cencora’s lowered fiscal 2026 revenue-growth outlook reflects WAC and IRA-related price reductions, faster brand conversions at a major mail-order customer, slower GLP-1 growth and customer losses. Analyst target reductions after the outlook reset likely reinforced the recent decline. Cencora Slides as Investors Remain Cautious on Revenue Headwinds

Cencora Company Profile

(Get Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.